Labeling Requirements for Selective COX-2 Inhibitors
- Include black boxed warnings specifying risk of CV events and potentially life-threatening GI bleeding, plus relevant contraindications.
- Remind practitioners to use the lowest effective dose for the shortest duration needed.
- Manufacturers must commit to long-term safety studies and monitoring.
- Mandatory inclusion of patient leaflets providing safety information.
Labeling Requirements for Prescription Nonselective NSAIDs
- Incorporate boxed warnings regarding CV risk and potentially serious GI adverse events.
- Contraindicate use in patients undergoing Coronary Artery Bypass Graft (CABG) surgery.
- Include instructions advising patients to consult doctors about risks/benefits and to use the lowest effective dose for the shortest time.
Labeling and Market Conditions for OTC NSAIDs
- No current data suggesting increased serious CV risk for short-term, low dose OTC NSAID use.
- Allowed on the market provided package inserts are revised with:
- Specific CV and GI risk information.
- Strong warnings on dose limits and treatment duration.
- Warnings on potential skin reactions prompting discontinuation.
- Public information campaign through posters and leaflets available in drug outlets.
Specific Absolute Contraindications for Selective COX-2 Inhibitors
- History of stroke (CVA), myocardial infarction (MI), CABG, congestive heart failure (NYHA II-IV).
- Placed prominently after dosage instructions on the first page of inserts.
Cautions and Additional Warnings for Selective COX-2 Inhibitors
- Avoid in patients allergic to NSAIDs or with asthma.
- Use caution in patients with ischemic heart disease, hypertension, hyperlipidemia, diabetes, smoking history, or peripheral arterial disease.
- Discontinue if skin rash or hypersensitivity occurs.
- Include warnings about potential gastrointestinal and renal toxicities.
Specific Absolute Contraindications for Prescription NSAIDs
- History of stroke, MI, CABG, uncontrolled hypertension, and congestive heart failure (NYHA II-IV).
- Placement of warning similar to COX-2 inhibitors: immediately after dosing instructions.
Additional Warnings for Prescription NSAIDs
- Contraindicated in patients with hypersensitivity to ASA or other NSAIDs.
- Contraindicated in patients with active or past peptic ulcer disease.
- Caution advised for those with cardiac, liver, and renal diseases; dose adjustments and monitoring recommended.
Public Information for OTC NSAIDs
- Posters in English and Tagalog must inform about:
- NSAID examples and potential side effects: bleeding stomach ulcers, liver impairment, kidney problems, fluid retention.
- Symptoms requiring discontinuation: stomach pain, black stools, jaundice, flu-like symptoms, swelling.
- Allergy warnings, especially about aspirin allergy.
- Advice for people with heart issues, hypertension, stomach ulcers, asthma, renal problems, or pregnancy to consult healthcare professionals.
Summary of Implementation
- Labeling changes are mandatory for all selective COX-2 inhibitors and prescription NSAIDs.
- OTC NSAIDs require label revisions and public awareness campaigns.
- Aspirin and Paracetamol are specifically excluded from these mandated changes due to their distinct pharmacological profiles and risk-benefit considerations.
- Emphasis on using the lowest effective doses and shortest duration across all NSAID use to minimize risks.